Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

Fractyl Health (Nasdaq: GUTS) will report third-quarter 2026 financial results and provide business updates on November 12, 2026, at 4:30 p.m. ET.

Rhea-AI Summary

Fractyl Health (Nasdaq: GUTS) will report third-quarter 2026 financial results and provide business updates on November 12, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation will be available in the Events section of the company’s investor website, with an archived replay available afterward.

Key Terms

t2d

1 terms

t2d medical

"obesity and type 2 diabetes (T2D)"

t2d is shorthand for type 2 diabetes, a common chronic condition in which the body struggles to use insulin properly, causing high blood sugar over time. Investors watch t2d because it represents a large, ongoing market for medicines, devices and care—like a steady stream of customers needing better treatments—so clinical trial results, approvals or new therapies can materially affect healthcare company revenues and stock values.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the third quarter 2026 and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.

To enhance engagement with the company's shareholder base, Fractyl Health is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered during the earnings call.

Shareholders can submit questions by visiting: https://app.saytechnologies.com/fractyl-health-2026-q3. This Q&A platform will remain open until 4:30 p.m. ET on November 11, 2026. Shareholders can email support@saytechnologies.com for any support inquiries.

About Fractyl Health 

Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl’s goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Contact 

Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can Fractyl Health shareholders submit questions for the third-quarter 2026 earnings call?

Retail and institutional shareholders can submit and upvote questions at https://app.saytechnologies.com/fractyl-health-2026-q3 until 4:30 p.m. ET on November 11, 2026. A selection of questions will be answered during the earnings call. Support inquiries can be emailed to support@saytechnologies.com.